Apixaban Shows Safer Profile Than Rivaroxaban for Venous Thrombosis Treatment

New research published in the New England Journal of Medicine on March 12, 2026, indicates that apixaban (Eliquis) is associated with a lower risk of clinically relevant bleeding compared to rivaroxaban (Xarelto) in patients treated for venous thrombosis. The findings offer valuable insights for physicians and patients navigating treatment options for conditions like deep-vein thrombosis and pulmonary embolism.

Study Details and Findings

Researchers analyzed data from 2,760 individuals diagnosed with acute symptomatic pulmonary embolism or proximal deep-vein thrombosis across Canada, Australia, and Ireland. Participants were divided into two groups: 1,370 received apixaban, while 1,390 were treated with rivaroxaban. Both medications are direct oral anticoagulants (DOACs).

Over a three-month period, 7.1% of patients taking rivaroxaban experienced clinically relevant bleeding, significantly higher than the 3.3% observed in the apixaban group. Importantly, the study found no significant difference between the two drugs regarding the risk of recurrent blood clots.

Implications for Clinical Practice

Lana A. Castellucci, lead study author and senior scientist at the Ottawa Hospital, emphasized the significance of the results, stating, “These results clearly show that apixaban is the safer option for treating venous thrombosis.”

The study provides physicians with evidence to support informed decision-making when prescribing anticoagulants for venous thromboembolism. For patients, the findings may offer reassurance regarding bleeding risk, a common concern associated with these medications.

Understanding Venous Thrombosis and Anticoagulants

Venous thrombosis, encompassing conditions like deep-vein thrombosis (DVT) and pulmonary embolism (PE), occurs when a blood clot forms in a vein. These clots can cause pain, swelling, and potentially life-threatening complications. Anticoagulants, often referred to as blood thinners, are crucial in preventing clot formation and allowing the body to break down existing clots.

DOACs like apixaban and rivaroxaban have grow increasingly popular alternatives to traditional anticoagulants like warfarin, offering advantages such as predictable dosing and reduced demand for routine monitoring. However, bleeding risk remains a key consideration when selecting an anticoagulant.

Further Research and Considerations

While this study provides compelling evidence regarding the safety profile of apixaban, ongoing research continues to refine our understanding of optimal anticoagulant strategies. Factors such as patient-specific characteristics, co-existing medical conditions, and potential drug interactions should be carefully considered when individualizing treatment plans.

The New England Journal of Medicine also published research on other topics this week, including comparisons of oral anticoagulants and treatment for chemotherapy-induced thrombocytopenia.